Mereo BioPharma Group plc Net Assets
Mereo BioPharma Group plc net assets. Based on the latest financial reports, Mereo BioPharma Group plc (MAH0) has net assets worth €40.92 Million EUR (≈ $47.84 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€45.92 Million ≈ $53.68 Million USD) and total liabilities (€5.00 Million ≈ $5.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Mereo BioPharma Group plc annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €40.92 Million |
| % of Total Assets | 89.11% |
| Annual Growth Rate | -7.08% |
| 5-Year Change | -53.51% |
| 10-Year Change | N/A |
| Growth Volatility | 46.61 |
Net Assets of Mereo BioPharma Group plc (2016–2025)
Net assets of Mereo BioPharma Group plc from 2016 to 2025. This chart illustrates how Mereo BioPharma Group plc's net assets have evolved over time, based on quarterly financial data. See MAH0 net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Mereo BioPharma Group plc (2016–2025)
The table below shows the annual net assets of Mereo BioPharma Group plc from 2016 to 2025. For live market cap and overall valuation, see market cap of Mereo BioPharma Group plc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €40.92 Million ≈ $47.84 Million |
-32.89% |
| 2024-12-31 | €60.97 Million ≈ $71.28 Million |
+20.64% |
| 2023-12-31 | €50.54 Million ≈ $59.08 Million |
-18.31% |
| 2022-12-31 | €61.87 Million ≈ $72.33 Million |
-29.70% |
| 2021-12-31 | €88.00 Million ≈ $102.88 Million |
+687.82% |
| 2020-12-31 | €-14.97 Million ≈ $-17.50 Million |
-137.19% |
| 2019-12-31 | €40.26 Million ≈ $47.06 Million |
+22.84% |
| 2018-12-31 | €32.77 Million ≈ $38.31 Million |
-47.55% |
| 2017-12-31 | €62.48 Million ≈ $73.05 Million |
-21.16% |
| 2016-12-31 | €79.26 Million ≈ $92.66 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Mereo BioPharma Group plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46043875900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Mereo BioPharma Group plc Net Assets Breakdown (December 2025)
Mereo BioPharma Group plc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €541.93 Million | 1324.50% |
| Total Equity | €40.92 Million | 100.00% |
Mereo BioPharma Group plc Competitors by Market Cap
The table below lists competitors of Mereo BioPharma Group plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Poulaillon SA
PA:ALPOU
|
$31.94 Million |
|
Ironbark Capital Ltd
AU:IBC
|
$31.95 Million |
|
Datron AG
XETRA:DAR
|
$31.95 Million |
|
Jeil Technos Co.Ltd
KQ:038010
|
$31.96 Million |
|
Chow Steel Industries Public Company Limited
BK:CHOW
|
$31.92 Million |
|
Bowim S.A.
WAR:BOW
|
$31.90 Million |
|
TDb Split Corp
TO:XTD
|
$31.88 Million |
|
Hitech Group Australia Ltd
AU:HIT
|
$31.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mereo BioPharma Group plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 60,969,000 to 40,916,000, a change of -20,053,000 (-32.9%).
- Net loss of 41,878,000 reduced equity.
- New share issuances of 39,000 increased equity.
- Other factors increased equity by 21,786,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-41.88 Million | -102.35% |
| Share Issuances | €39.00K | +0.1% |
| Other Changes | €21.79 Million | +53.25% |
| Total Change | €- | -32.89% |
Book Value vs Market Value Analysis
This analysis compares Mereo BioPharma Group plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.94x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.29x to 4.94x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.88 | €0.25 | x |
| 2018-12-31 | €0.46 | €0.25 | x |
| 2019-12-31 | €0.41 | €0.25 | x |
| 2020-12-31 | €-0.04 | €0.25 | x |
| 2021-12-31 | €0.15 | €0.25 | x |
| 2022-12-31 | €0.10 | €0.25 | x |
| 2023-12-31 | €0.07 | €0.25 | x |
| 2024-12-31 | €0.08 | €0.25 | x |
| 2025-12-31 | €0.05 | €0.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mereo BioPharma Group plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -102.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8375.60%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.12x
- Recent ROE (-102.35%) is below the historical average (-55.46%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -35.82% | 0.00% | 0.00x | 1.09x | €-36.32 Million |
| 2017 | -62.09% | 0.00% | 0.00x | 1.54x | €-45.05 Million |
| 2018 | -97.74% | 0.00% | 0.00x | 2.05x | €-35.31 Million |
| 2019 | -86.56% | 0.00% | 0.00x | 2.15x | €-38.87 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | €-162.13 Million |
| 2021 | 14.46% | 34.90% | 0.29x | 1.44x | €3.92 Million |
| 2022 | -55.27% | 0.00% | 0.00x | 1.42x | €-40.38 Million |
| 2023 | -58.31% | -294.66% | 0.15x | 1.32x | €-34.52 Million |
| 2024 | -70.94% | 0.00% | 0.00x | 1.25x | €-49.35 Million |
| 2025 | -102.35% | -8375.60% | 0.01x | 1.12x | €-45.97 Million |
Industry Comparison
This section compares Mereo BioPharma Group plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mereo BioPharma Group plc (MAH0) | €40.92 Million | -35.82% | 0.12x | $31.92 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung dise… Read more